The House of Delegates (HOD) is ACCC’s policy-making body. It consists of voting Delegate Representatives from each of ACCC’s Cancer Program members. Each spring, Delegate Representatives convene at the ACCC Annual Meeting to hear Association updates and vote on bylaws and dues changes.
Each Delegate Representative participates in the Association by helping their cancer program maximize the benefit of membership through activities including:
ACCC's inaugural class of Fellows (FACCC) stand together at the conclusion of the 2022 House of Delegates meeting. (Left to right, ACCC Membership Committee Chair Jeff Hunnicutt (at podium); 2020-2021 President, Randall A. Oyer, MD; 2018-2019 President, Thomas A. Gallo, MS, MDA; 2016-2017 President, Jennie R. Crews, MD, MMM, FACP; 2015-2016 President, Steven L. D’Amato, BscPharm; 2014-2015 President, Becky L. DeKay, MBA; 2013-2014 President, Virginia T. Vaitones, MSW, OSW-C; 1997-1998 President, James L. Wade III, MD, FACP; 2010-2011 President, Al B. Benson, III, MD, FACP; 2017-2018 President, Mark S. Soberman, MD, MBA, FACS.)
President David R. Penberthy, MD, MBA, unveils the theme of his presidency at the House of Delegates meeting.
ACCC Executive Director Christian Downs shares the 2021 Impact Report— which highlights the strategic initiatives and accomplishments during the previous twelve months, in addition to a snapshot of ACCC’s financial position. The Annual Report is presented each March at the House of Delegates Meeting at the Annual Meeting & Cancer Center Business Summit (#AMCCBS) in Washington, D.C.
ACCC Immediate Past-President, Krista Nelson, MSW, LCSW, shares the importance of investing in social workers, and why their role is essential to delivering quality cancer care to patients and their families.